Akaza Research and Conecta Join Forces for OpenClinica in Italy
OpenClinica, an open source EDC system, to hit the Italian market thanks to a new partnership.
Cambridge, MA-June 12th, 2008-Conecta, an Italian open source consulting company, and Akaza Research, developers of OpenClinica, the leading open source Electronic Data Capture (EDC) software, jointly announce a development partnership aimed at bringing OpenClinica and OpenClinica Enterprise to the Italian clinical research market.
"OpenClinica is the most advanced open source EDC system in the market today", said Carlo Daffara, research director at Conecta. "After extensive evaluation, we found the tool to be flexible, complete, and well developed according to best practices in the clinical research software market. The flexibility of open source and the validated approach help in bringing EDC to new markets that have been until now, locked into proprietary and inflexible solutions."
”We are pleased to be working with Conecta,” said Benjamin Baumann, director of business development at Akaza Research. “This partnership will further strengthen OpenClinica’s presence across Europe, allowing more researchers to benefit from a professionally supported open source solution.”
OpenClinica is already in trial use at the Disability Italian Network and the Tuscany Region, in a specialized study based on the WHO ICF protocol, and is being implemented for the Regional Health Care Authority of the Friuli-Venezia Giulia region. An early outcome is the development of an Italian localization of OpenClinica that is expected to be included in the next production release of the product. In addition, the groups will share code and best practices for the dynamic forms and complex validation functionalities.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
